GlobeNewsWire
25 Aug 2026, 22:33 UTC · 1w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
ResMed reported lower-than-expected adjusted gross margins and operating income for its fiscal 2026 fourth quarter. — Misses on key profitability metrics typically lead to downward revisions of valuation and analyst expectations.
-0.60ResMed incurred approximately $42 million in field safety notification expenses due to leak issues with its Astral respirators. — Product safety issues and unexpected costs signal operational failures and potential future liability/reputational risk.
-0.40Pomerantz LLP is investigating ResMed for potential securities fraud or other unlawful business practices. — The initiation of a securities fraud investigation increases the risk of costly class-action litigation and regulatory scrutiny.
-0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is under investigation for potential securities fraud following a stock price drop and reports of product safety issues.
The company is the subject of an investigation by a law firm on behalf of investors.
The company is the subject of an investigation by a law firm on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
5h ago
